News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026February 5, 2026
Elixinol records first underlying operating cash flow positive quarter by Adam Sheldon February 2, 2026February 3, 2026
InhaleRx locks in A$1m cap raise and reveals plans to rebrand by Adam Sheldon December 1, 2025February 21, 2026
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
News in brief: InhaleRx; Hemp Pet; Neurotech International; Cann Group by Martin Lane November 19, 2024April 11, 2025
